Read More

Bristol Myers Squibb-Pfizer Alliance Presents results from ATHENS Retrospective Observational Study Assessing Real-World Clinical Impact Of Switching Or Continuing Eliquis Or Rivaroxaban Presented At The European Society Of Cardiology Congress 2023

Switching from Eliquis (apixaban) to rivaroxaban in Non-Valvular Atrial Fibrillation (NVAF) patients was associated with a higher risk of stroke/systemic embolism (S/SE) and major bleeding (MB) than those who continued

BMY